deferoxamine has been researched along with Agranulocytosis in 9 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia." | 4.82 | Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| "Agranulocytosis was observed in a 63-year-old patient with myelodysplasia 6 weeks after commencing chelation with the oral iron chelator deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1) at a daily dose of 79 mg/kg." | 3.69 | The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system. ( al-Rafaie, FN; Hoffbrand, AV; Wilkes, S; Wonke, B, 1994) |
| "Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvaruso, G | 1 |
| Vitrano, A | 1 |
| Di Maggio, R | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Gerardi, C | 1 |
| Rigoli, LC | 1 |
| Sacco, M | 1 |
| Pitrolo, L | 1 |
| Maggio, A | 1 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Cinque, P | 1 |
| Lanza, AG | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Di Costanzo, G | 1 |
| Pagano, L | 1 |
| Prossomariti, L | 1 |
| Origa, R | 1 |
| Bina, P | 1 |
| Agus, A | 2 |
| Crobu, G | 1 |
| Defraia, E | 1 |
| Dessì, C | 2 |
| Leoni, G | 1 |
| Muroni, PP | 1 |
| Galanello, R | 2 |
| Kattamis, A | 1 |
| Piga, A | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Tanner, MA | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| al-Rafaie, FN | 1 |
| Wilkes, S | 1 |
| Wonke, B | 1 |
| Hoffbrand, AV | 1 |
| Hershko, C | 1 |
| Richardson, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for deferoxamine and Agranulocytosis
| Article | Year |
|---|---|
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
2 trials available for deferoxamine and Agranulocytosis
| Article | Year |
|---|---|
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
4 other studies available for deferoxamine and Agranulocytosis
| Article | Year |
|---|---|
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |
The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system.
Topics: Agranulocytosis; Bone Marrow; Cell Division; Cells, Cultured; Deferiprone; Deferoxamine; Humans; Mid | 1994 |
Development of oral iron chelator L1.
Topics: Agranulocytosis; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Thalassemia | 1993 |